FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
The plant is expected to start commercial operations from Q4FY24
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Subscribe To Our Newsletter & Stay Updated
